EP4731221A1 - Combinaison comprenant un dérivé de désoxycytidine et un inhibiteur de parp destiné à être utilisé dans une méthode de traitement du cancer déficient en hr - Google Patents

Combinaison comprenant un dérivé de désoxycytidine et un inhibiteur de parp destiné à être utilisé dans une méthode de traitement du cancer déficient en hr

Info

Publication number
EP4731221A1
EP4731221A1 EP24736724.6A EP24736724A EP4731221A1 EP 4731221 A1 EP4731221 A1 EP 4731221A1 EP 24736724 A EP24736724 A EP 24736724A EP 4731221 A1 EP4731221 A1 EP 4731221A1
Authority
EP
European Patent Office
Prior art keywords
cancer
cells
5hm2dc
5f2dc
proficient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24736724.6A
Other languages
German (de)
English (en)
Inventor
Adam Brian ROBERTSON
Terezia PRIKRYLOVA
Thea Sofie Follum AUDSEN
Sandra CANTILENA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tetragon Biosciences Ltd
Original Assignee
Tetragon Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tetragon Biosciences Ltd filed Critical Tetragon Biosciences Ltd
Publication of EP4731221A1 publication Critical patent/EP4731221A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Molecular Biology (AREA)

Abstract

La présente invention concerne une combinaison pharmaceutique destinée à être utilisée dans une méthode de traitement d'un cancer déficient en HR, la combinaison pharmaceutique comprenant un inhibiteur de PARP et un composé de Formule (I): ou un stéréoisomère, un solvate, un tautomère ou un sel pharmaceutiquement acceptable de celui-ci, X, Y, Z, W1, W2, R1, R2 et R3 étant tels que définis dans la présente divulgation. La présente invention concerne également des méthodes de traitement du cancer déficient en HR comprenant l'administration de la combinaison pharmaceutique à un sujet en ayant besoin, et des compositions pharmaceutiques et des kits comprenant de telles combinaisons pharmaceutiques.
EP24736724.6A 2023-06-21 2024-06-21 Combinaison comprenant un dérivé de désoxycytidine et un inhibiteur de parp destiné à être utilisé dans une méthode de traitement du cancer déficient en hr Pending EP4731221A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB202309340 2023-06-21
PCT/EP2024/067440 WO2024261243A1 (fr) 2023-06-21 2024-06-21 Combinaison comprenant un dérivé de désoxycytidine et un inhibiteur de parp destiné à être utilisé dans une méthode de traitement du cancer déficient en hr

Publications (1)

Publication Number Publication Date
EP4731221A1 true EP4731221A1 (fr) 2026-04-29

Family

ID=91699942

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24736724.6A Pending EP4731221A1 (fr) 2023-06-21 2024-06-21 Combinaison comprenant un dérivé de désoxycytidine et un inhibiteur de parp destiné à être utilisé dans une méthode de traitement du cancer déficient en hr

Country Status (7)

Country Link
EP (1) EP4731221A1 (fr)
KR (1) KR20260030809A (fr)
CN (1) CN121398822A (fr)
AU (1) AU2024312126A1 (fr)
IL (1) IL325458A (fr)
MX (1) MX2025014445A (fr)
WO (1) WO2024261243A1 (fr)

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0412848B1 (fr) 1989-08-11 1995-01-18 Zeneca Limited Dérivés de quinoléine, procédés pour leur préparation et leur utilisation comme médicaments
IE903911A1 (en) 1989-11-20 1991-05-22 Ici Plc Diazine derivatives
GB2244054B (en) 1990-04-19 1994-04-06 Ici Plc Pyridine derivatives
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US6495541B1 (en) 1999-01-11 2002-12-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
AU2004200A (en) 1999-01-14 2000-08-01 Meiji Seika Kaisha Ltd. Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
AU7314200A (en) 1999-09-17 2001-04-24 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
EP1183259A2 (fr) 1999-09-28 2002-03-06 Basf Aktiengesellschaft Derives d'azepinoindol, preparation et utilisation desdits derives
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6444676B1 (en) 1999-12-20 2002-09-03 Iok-Hou Pang Use of PARP inhibitors in the treatment of glaucoma
DE50112961D1 (de) 2000-02-01 2007-10-18 Abbott Gmbh & Co Kg Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
AU2001248748A1 (en) 2000-04-18 2001-10-30 Sumitomo Pharmaceuticals Company, Limited Substituted piperazine compounds
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US20060276497A1 (en) 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
WO2001090077A1 (fr) 2000-05-19 2001-11-29 Guilford Pharmaceuticals, Inc. Derives de sulfonamide et de carbamide de 6(5h) phenanthridinones et utilisations de ceux-ci
WO2001091796A2 (fr) 2000-06-01 2001-12-06 Guilford Pharmaceuticals Inc. Methodes, composes et compositions permettant de traiter la goutte
GB0017508D0 (en) 2000-07-17 2000-08-30 Novartis Ag Antimicrobials
US6903101B1 (en) 2000-08-10 2005-06-07 Bayer Pharmaceuticals Corporation Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
HU228960B1 (hu) 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok
ITMI20002358A1 (it) 2000-10-31 2002-05-01 Flavio Moroni Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi
JP4323802B2 (ja) 2000-12-01 2009-09-02 エムジーアイ・ジーピー・インコーポレーテッド 化合物およびその使用
WO2002044157A2 (fr) 2000-12-01 2002-06-06 Iconix Pharmaceuticals, Inc. Inhibiteurs de la parp
EP1396488A1 (fr) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Compose heterocyclique condense et son utilisation medicale
JP3935363B2 (ja) 2001-06-26 2007-06-20 サカタインクス株式会社 水性顔料分散体の製造方法およびその方法から得られる水性顔料分散体
WO2003007959A1 (fr) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Derives de quinoxaline ayant une action inhibitrice sur parp
WO2003014121A1 (fr) 2001-08-07 2003-02-20 Guilford Pharmaceuticals Inc. Composes, derives, compositions, leur preparation et leurs utilisations
WO2003051879A1 (fr) 2001-12-14 2003-06-26 Altana Pharma Ag 4,5-dihydro-imidazo[4,5,1-ij]quinoline-6-ones connues et nouvelles utilisees en tant qu'inhibiteurs de la poly(adp-ribose)polymerase
WO2003057145A2 (fr) 2001-12-31 2003-07-17 Guilford Pharmaceuticals Inc. 4,9-dihydrocyclopenta[imn]phenanthridine-5-ones substitues, leurs derives et leurs utilisations
US7026311B2 (en) 2002-01-10 2006-04-11 Abbott Gmbh & Co., Kg Dibenzodiazepine derivatives, their preparation and use
JPWO2004043959A1 (ja) 2002-11-12 2006-03-09 持田製薬株式会社 新規ｐａｒｐ阻害剤
TW200412959A (en) 2002-11-22 2004-08-01 Mitsubishi Pharma Corp Isoquinoline compounds and medicinal use thereof
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
CA2520997A1 (fr) 2003-03-31 2004-10-14 Stacie Sara Canan-Koch Sels d'inhibiteurs tricycliques de poly(adp-ribose) polymerases
HU227948B1 (en) 2003-04-30 2012-07-30 Pecsi Tudomanyegyetem Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme
ES2396334T3 (es) 2003-05-28 2013-02-20 Eisai Inc. Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP
WO2004108723A1 (fr) 2003-06-04 2004-12-16 Altana Pharma Ag 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones utilisees comme inhibiteurs de parp
US7531530B2 (en) 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
WO2005023246A1 (fr) 2003-09-04 2005-03-17 Aventis Pharmaceuticals Inc. Indoles substitues comme inhibiteurs de polymerase de poly(adp-ribose) (parp)
JP2007504209A (ja) 2003-09-04 2007-03-01 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー ＰＩ３Ｋ阻害活性を有する治療薬としてのハロゲン置換ベンゾ（ｂ）チオフェン類
BRPI0416206A (pt) 2003-11-20 2006-12-26 Janssen Pharmaceutica Nv 2-quinolinonas e 2-quinoxalinonas substituìdas por 6-alquenila e 6-fenilalquila como inibidores de polimerase de poli(adp-ribose)
CA2546002C (fr) 2003-11-20 2012-09-18 Janssen Pharmaceutica N.V. 2-quinolinones et 2 quinoxalinones a substitution 7-phenylalkyl tenant lieu d'inhibiteurs de poly(adp-ribose) polymerase inhibitors
SG151249A1 (en) 2003-12-05 2009-04-30 Janssen Pharmaceutica Nv 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
US7652014B2 (en) 2003-12-10 2010-01-26 Janssen Pharmaceutica Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
DE202004003061U1 (de) 2004-02-25 2005-07-14 Kronospan Technical Company Ltd., Engomi Dekorpapier mit elektrisch geladenen Fasern
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
WO2005108400A1 (fr) 2004-05-11 2005-11-17 Mochida Pharmaceutical Co. Ltd. Dérivés de pyridoquinazoline ayant des substituants hétérobicycliques
CA2566436C (fr) 2004-05-13 2011-05-10 Vanderbilt University Inhibiteurs selectifs de la phosphoinositide-3-kinase delta pour inhiber l'angiogenese
DE102004028973A1 (de) 2004-06-16 2006-01-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
EA011552B1 (ru) 2004-06-30 2009-04-28 Янссен Фармацевтика Н.В. Производные хиназолиндиона в качестве ингибиторов parp
SG154433A1 (en) 2004-06-30 2009-08-28 Janssen Pharmaceutica Nv Phthalazine derivatives as parp inhibitors
ATE540936T1 (de) 2004-06-30 2012-01-15 Janssen Pharmaceutica Nv Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
US8466144B2 (en) 2004-07-16 2013-06-18 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
ATE551345T1 (de) 2004-09-22 2012-04-15 Pfizer Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on
PT1794163E (pt) 2004-09-22 2010-03-01 Pfizer Método para a preparação de inibidores de poli(adpribose)- polimerases
MX2007003314A (es) 2004-09-22 2007-08-06 Pfizer Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas.
DE102004050196A1 (de) 2004-10-15 2006-04-20 Sanofi-Aventis Deutschland Gmbh Substituierte 2-Pyridon-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
MX2007005361A (es) 2004-11-05 2008-01-11 Cephalon Inc Tratamientos para cancer.
EP1831207B1 (fr) 2004-12-17 2012-11-14 Amgen Inc. Composes d'aminopyrimidine comme inhibiteurs de plk
US20060204981A1 (en) 2005-01-07 2006-09-14 Chiang Li Compositions for modulation of PARP and methods for screening for same
US7820668B2 (en) 2005-01-19 2010-10-26 Eisai Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting PARP
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
CN101233121A (zh) 2005-06-10 2008-07-30 彼帕科学公司 Parp调节剂和癌症的治疗
WO2006137510A1 (fr) 2005-06-24 2006-12-28 Ono Pharmaceutical Co., Ltd. Agent pour réduire le saignement lors de troubles cérébrovasculaires
ZA200800907B (en) 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
JP5227796B2 (ja) 2005-09-29 2013-07-03 アボット・ラボラトリーズ ２位においてフェニルによって置換された１ｈ−ベンズイミダゾール−４−カルボキサミドは強力なｐａｒｐ阻害薬である
CA2647545C (fr) 2006-04-03 2016-02-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Utilisation de derives de benzotriazole et d'indazole amide substitue comme inhibiteurs de la poly(adp-ribose)polymerase (parp)
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
US20090181951A1 (en) 2006-06-15 2009-07-16 Kudos Pharmaceuticals Limited Parp inhibitors
WO2007144639A1 (fr) 2006-06-15 2007-12-21 Kudos Pharmaceuticals Limited Dérivés d'oxybenzamide 2 en tant qu'inhibiteurs d'activité parp
US20090281086A1 (en) 2006-06-15 2009-11-12 Kudos Pharmaceuticals Limited 2 -oxyheteroarylamide derivatives as parp inhibitors
WO2008015429A2 (fr) 2006-08-01 2008-02-07 Sentinel Oncology Limited Composés pharmaceutiques
US20100249112A1 (en) 2007-05-25 2010-09-30 Astrazeneca R&D Combination of chk and parp inhibitors for the treatment of cancers
ES2504690T3 (es) 2007-10-03 2014-10-08 Eisai Inc. Compuestos inhibidores de PARP, composiciones y métodos de uso
SA109300394B1 (ar) 2008-06-19 2013-01-22 ويث ثيازوليل- وأوكسازوليل- أيزوكوينولينونات وطرق لاستخدامها
CN102307475A (zh) 2009-02-04 2012-01-04 彼帕科学公司 用与生长因子抑制剂组合的parp抑制剂治疗肺癌
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
SG2014014294A (en) 2011-04-11 2014-06-27 Abbvie Inc Parp inhibitors for the treatment of cipn
CN104003979B (zh) 2013-02-21 2016-08-17 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪类化合物、其药物组合物及其制备方法和用途
CN104140426B (zh) 2013-05-07 2017-02-01 上海汇伦生命科技有限公司 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途
CN104230896A (zh) 2013-06-17 2014-12-24 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
US20190365745A1 (en) * 2018-06-01 2019-12-05 Cornell University Use of chronic treatment with atr inhibitors to sensitize cancer cells to parp inhibitors
CN118118644A (zh) 2018-09-27 2024-05-31 美国斯耐普公司 可分离失真视差确定
GB2580963C (en) 2019-02-01 2025-09-03 Hemispherian As Cancer therapies
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
WO2021162120A1 (fr) 2020-02-14 2021-08-19 公立大学法人横浜市立大学 Construction d'acide nucléique pouvant mesurer une activité de recombinaison homologue, et son procédé d'utilisation

Also Published As

Publication number Publication date
CN121398822A (zh) 2026-01-23
IL325458A (en) 2026-02-01
KR20260030809A (ko) 2026-03-06
WO2024261243A1 (fr) 2024-12-26
MX2025014445A (es) 2026-03-02
AU2024312126A1 (en) 2025-12-11

Similar Documents

Publication Publication Date Title
JP6963146B1 (ja) 癌を治療するためのｋｒａｓ阻害剤の投与
US20220175751A1 (en) Methods of Treating Ovarian Cancer
Michels et al. Predictive biomarkers for cancer therapy with PARP inhibitors
US20210093730A1 (en) Biomarkers for antibody-drug conjugate monotherapy or combination therapy
JP6783224B2 (ja) 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用
Underhill et al. A review of PARP inhibitors: from bench to bedside
JP2021508704A (ja) がんを処置する方法
TWI631949B (zh) 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
CN112472699A (zh) 改善比生群及衍生物的治疗益处的组合方法
CA2869557A1 (fr) Nouvelles compositions de combinaisons d'agents de liaison a l'adn non covalents et d'agents anticancereux et/ou anti-inflammatoires, et leur utilisation dans le traitement d'unemaladie
JP2018524382A (ja) キラルジアリール大環状分子及びその使用
US20220339179A1 (en) Treatment of hr deficient cancer
Park et al. Poly (Adenosine Diphosphate–Ribose) Polymerase Inhibitors in Cancer Treatment
Yang et al. Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
Leonetti et al. Targeted therapy for brain tumours: role of PARP inhibitors
US20160208339A1 (en) Biomarkers correlated to parp inhibitor treatment success in aml patients
Ampolini et al. The development of ATM inhibitors in cancer therapy
Comen et al. Inhibition of poly (ADP)-ribose polymerase as a therapeutic strategy for breast cancer
WO2017031156A1 (fr) Utilisation d'uréidomustine (bo-1055) dans le traitement du cancer
WO2024261243A1 (fr) Combinaison comprenant un dérivé de désoxycytidine et un inhibiteur de parp destiné à être utilisé dans une méthode de traitement du cancer déficient en hr
TW202535405A (zh) 用於藉由增強數類已核准藥物的作用以治療癌症之alc1抑制劑
US11957677B2 (en) Cancer treatment using FGFR inhibitors and PLK1 inhibitors
WO2024054898A1 (fr) Combinaison d'onvansertib et d'inhibiteur de parp
HK40113232A (en) Methods of treating ovarian cancer
HK40098135A (en) Methods of treating ovarian cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR